Arcus Biosciences, Inc. (RCUS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 90M 180M 270M Q3 '24: 263M Q4 '24: 258M Q1 '25: 141M Q2 '25: 262M Q3 '25: 240M Q4 '25: 247M Q1 '26: 236M Q2 '26: 117M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-600M -400M -200M 0 200M 400M 600M Q3 '24: -318M Q4 '24: -330M Q1 '25: -436M Q2 '25: -338M Q3 '25: -375M Q4 '25: -386M Q1 '26: -398M Q2 '26: -486M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income TTM

-600M -400M -200M 0 200M 400M 600M Q3 '24: -270M Q4 '24: -283M Q1 '25: -391M Q2 '25: -298M Q3 '25: -341M Q4 '25: -353M Q1 '26: -369M Q2 '26: -460M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-600M -400M -200M 0 200M 400M 600M Q3 '24: -158M Q4 '24: -170M Q1 '25: -300M Q2 '25: -339M Q3 '25: -462M Q4 '25: -482M Q1 '26: -488M Q2 '26: -474M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow TTM

-600M -400M -200M 0 200M 400M 600M Q3 '24: -169M Q4 '24: -176M Q1 '25: -303M Q2 '25: -342M Q3 '25: -464M Q4 '25: -484M Q1 '26: -489M Q2 '26: -475M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '24: 86.2M Q2 '24: 91.1M Q3 '24: 91.4M Q1 '25: 98.4M Q2 '25: 106.5M Q3 '25: 106.5M Q1 '26: 125.4M Q2 '26: 126.1M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '24: -3.15 Q4 '24: -3.10 Q1 '25: -4.19 Q2 '25: -3.17 Q3 '25: -3.44 Q4 '25: -3.31 Q1 '26: -3.19 Q2 '26: -3.91 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.